In 2023, the anxiolytic medicine sales in Canada stood at an undisclosed value from which the forecasts are projected. The forecasted trend from 2024 to 2028 shows a consistent decline in sales value, starting from $110 million USD PPP in 2024 and decreasing to $102.7 million USD PPP by 2028. This denotes a year-on-year decline in sales figures, with a Compound Annual Growth Rate (CAGR) reflecting this downward trajectory over the five-year period.
Future trends to watch include potential changes in healthcare policies, shifts in population mental health needs, and the introduction of new pharmaceutical innovations or generics that may influence the demand for anxiolytic medicines in the Canadian market.
